Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulmimetostat in Advanced Mycosis Fungoides and Sézary Syndrome
NCT05944562Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tulmimetostat in mycosis fungoides (MF) and Sézary syndrome (SS) (3 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Frequency and grades of treatment-emergent adverse events at 13 months and Rate of treatment discontinuation due to treatment-emergent adverse events at 13 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
tulmimetostat
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT05944562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944562.